Rotavirus Vaccine Phase III Trials May Require 60,000 - 100,000 Patients
Executive Summary
Rotavirus vaccine Phase III studies may require between 60,000 and 100,000 patients to address rare adverse event risks, Thomas Fleming, PhD, University of Washington, said during the Vaccines & Related Biological Products Advisory Committee meeting May 11.
You may also be interested in...
Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK
Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S
Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK
Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S
Rotavirus Vaccine Workshop May Address Intussusception Biomarker Data
A potential rotavirus vaccine-related intussusception biomarker could be a topic at a September workshop organized by the Centers for Disease Control & Prevention's National Vaccine Program Office and the National Vaccine Advisory Committee.